Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Complete title: A Pilot Study to Estimate the Safety and Tolerability of the Combination of Polatuzumab Vedotin with Dose Adjusted Rituximab, Etoposide, Cyclophosphamide, and Doxorubicin (DA-EPCH-PR) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas
Research Study Description
This trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy for the treatment of patients with untreated large B-cell lymphoma that grows and spreads quickly and has severe symptoms (aggressive). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in combination chemotherapy such as etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving polatuzumab vedotin in addition to etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab may help treat patients with aggressive large B-cell lymphoma.
Eligibility Criteria (must meet the following to participate in this
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Lymphoma, Non-Hodgkin (NHL); Lymphoma, Large B-Cell, Diffuse; Lymphoma, B-Cell Non-Hodgkin
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.